Latest Cinacalcet Stories
Third Phase 3 Study Met Non-Inferiority and Superiority Endpoints in the Reduction of Parathyroid Hormone THOUSAND OAKS, Calif., Feb.
Second Phase 3 Registrational Study Meets Primary and All Secondary Endpoints THOUSAND OAKS, Calif., Aug.
Analysis Shows Study Met Primary and All Secondary Endpoints THOUSAND OAKS, Calif., July 17, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that a Phase 3 study evaluating
Cinacalcet, a drug commonly given to patients with end stage kidney disease to help keep phosphorus and parathyroid blood levels within a target range and has few patient level clinical benefits and several adverse effects, suggesting that it should no longer be routinely prescribed.
Officials with the US Food and Drug Administration have halted a trial of the thyroid drug Sensipar following the death of a 14-year-old patient during clinical trials, various media outlets reported Tuesday.
In one of the largest and longest trials involving patients with kidney failure, a study led by an international team of researchers found that cinacalcet — a drug commonly prescribed to patients with kidney failure and a disturbance of bone and mineral metabolism known as secondary hyperparathyroidism — does not significantly reduce the risk of death or major cardiovascular events.
PRAGUE, June 28, 2011 /PRNewswire/ -- The 48th ERA-EDTA congress was the setting for a wide range of new clinical data.
- A woman chauffeur.
- A woman who operates an automobile.